[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Recker R.R., Akhter M.P., Lappe J.M., Watson P
Even after shortages eased, some companies continued offering compounded alternatives, leading to ongoing disputes with pharmaceutical manufacturers
Gallbladder-related adverse events, including cholelithiasis and cholecystitis, have been reported more frequently in patients receiving semaglutide compared to placebo in clinical trials, with an incidence of approximately two to three percent
Rights and permissions Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made